Glenmark Releases antiviral drug Favipiravir for Covid 19

New Delhi, Jun 20 (PTI) Drug firm Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 at a price of about Rs 103 per tablet.

The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.

FabiFlu is the first oral favipiravir-approved medication in India for the treatment of COVID-19, it said in a statement.

It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followe…

Spread the love
Ad Widget

Recommended For You

About the Author: JournalistEye

Leave a Reply

Your email address will not be published. Required fields are marked *